Yutao Gong, Ph.D.
About Yutao Gong, Ph.D.
Yutao Gong, Ph.D., is the Director of Data Governance and Regulatory Analytics at BeiGene, with a background in regulatory analytics and data science from his tenure at the FDA and various research roles.
Company
Yutao Gong, Ph.D., currently serves as the Director of Data Governance and Regulatory Analytics at BeiGene. He has been with the company since 2020, initially holding the role of Director, Regulatory Analytics. BeiGene is a global biotechnology company focused on developing and commercializing innovative medicines to improve treatment outcomes and quality of life for patients worldwide.
Title
As the Director of Data Governance and Regulatory Analytics at BeiGene, Yutao Gong, Ph.D., oversees the development and implementation of data governance frameworks. He ensures compliance with regulatory requirements and drives initiatives to enhance data quality and integrity.
Education and Expertise
Yutao Gong, Ph.D., holds a Ph.D. in Physics from the University of Wisconsin-Madison, where he studied from 2009 to 2013. He also holds a B.S. in Physics from Wuhan University and spent a year at the University of Illinois Chicago studying Physics. He has authored several peer-reviewed publications and presented research findings at international conferences. His certifications in advanced data analytics and regulatory compliance underscore his expertise in the field.
Previous Roles
Before joining BeiGene, Yutao Gong, Ph.D., held multiple roles at the FDA, including Lead Data Scientist - Office of Oncologic Diseases, Senior Staff Fellow, and Staff Fellow. He also worked at Thomas Jefferson University Hospital as a Research Fellow and served as a consultant for the American College of Radiology. His diverse roles have equipped him with a comprehensive understanding of data governance and regulatory analytics.
Achievements
At BeiGene, Yutao Gong, Ph.D., developed a proprietary data governance framework adopted by multiple departments. He also led a cross-functional team to implement a new regulatory analytics platform, improving compliance reporting efficiency by 30%. During his tenure at the FDA, he contributed to the development of guidelines on data integrity and governance. He actively mentors junior data scientists and participates in industry panels discussing the future of data governance.